We have recently shown that UDCA is a weak GPBAR1 ligand61 and clinical studies have confirmed that UDCA increases GLP1 release form the intestine63 and there is evidence that UDCA ameliorates insulin sensitivity in NAFLD patients. This evidence concerns the gene GPBAR1 and metabolic dysfunction-associated steatotic liver disease.